CDC

23 patient groups letter to Senate Appropriations in support of additional FY26 hepatitis programs funding

We the undersigned 23 organizations urge you to protect and, if possible, increase funding for domestic viral hepatitis programs at the Centers for Disease Control and Prevention (CDC).  At a time when we have tools including vaccines and curative treatments that can help eliminate viral hepatitis in the United States, we express our grave concern with the President’s FY 2026 budget request that eliminates $43 million in dedicated funding for hepatitis prevention. Instead, it proposes a $300 million block grant to states that would also include STD and tuberculosis prevention.

read more

23 patient groups letter to House Appropriations in support of additional FY26 hepatitis programs funding

We the undersigned 22 organizations urge you to protect and, if possible, increase funding for domestic viral hepatitis programs at the Centers for Disease Control and Prevention (CDC).  At a time when we have tools including vaccines and curative treatments that can help eliminate viral hepatitis in the United States, we express our grave concern with the President’s FY 2026 budget request that eliminates $43 million in dedicated funding for hepatitis prevention. Instead, it proposes a $300 million block grant to states that would also include STD and tuberculosis prevention.

read more

Senate testimony on FY26 appropriations for HIV and hepatitis

As a nation, we are able to advance efforts to end the HIV and viral hepatitis epidemics. We possess proven prevention tools, including pre-exposure prophylaxis medication (PrEP), and effective treatments. We urge you to continue your historically strong commitment and leverage this pivotal moment to support the nation’s public health by comprehensively addressing these chronic diseases. Increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis and allow us to continue to hold the promise of ending these epidemics.

read more

Senate testimony on FY25 appropriations for HIV and hepatitis programs

Our nation can eliminate both HIV and viral hepatitis, but without investing additional resources to accelerate our efforts, we will continue to fall short of these ambitious goals. Increased investment–and certainly not cuts–in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis, which include taking a syndemic approach to achieve maximum impact.

read more

House testimony on FY25 appropriations for HIV and hepatitis programs

Our nation can eliminate both HIV and viral hepatitis, but without an infusion of new resources to accelerate our efforts, we will continue to fall short of these ambitious goals. While we realize strict spending caps are in place, increased investment – and certainly not cuts – in surveillance, education, prevention, and care and treatment will lead to further progress in reducing HIV and viral hepatitis, which include taking a syndemic approach to achieve maximum impact. The programs and funding increases detailed below are pivotal to our nation’s ability to end both these potentially deadly infectious diseases.

read more

Pin It on Pinterest